Table 1.
Clinical characteristics of participants.
| CKD | Post-transplant CKD | Healthy control | p value (ANOVA) | |
|---|---|---|---|---|
| Stage 3 and 4 | Stage 3 and 4 | |||
| (n = 16) | (n = 16) | (n = 16) | ||
| A: Original cohort | ||||
| Age (years) | 58 ± 17 | 52 ± 14 | 36 ± 14 | 0.0017 |
| Gender (female %) | 31% | 50% | 75% | 0.05 |
| Race (Caucasian %) | 81% | 100% | 88% | 0.45 |
| History of DM (%) | 47% | 7% | 0% | 0.001 |
| BMI (kg/m2) | 29.0 ± 5.3 | 25.9 ± 4.3 | 25.2 ± 5.8 | 0.1 |
| SBP (mmHg) | 131 ± 14 | 135 ± 14 | 115 ± 12 | 0.0006 |
| DBP (mmHg) | 80 ± 8 | 83 ± 10 | 71 ± 8 | 0.002 |
| CKD-EPI eGFR (mL/min/1.73m2) | 41 ± 9 | 49 ± 10 | 100 ± 17 | < 0.0001 |
| ACR (mg/g) | 6 ± 17 | 1 ± 3 | 0.1 ± 0.1 | 0.02 |
| ACEi/ARB (%) | 73 | 30 | 0 | < 0.0001 |
| B: Validation Cohort* (n = 30) | ||||
| Age (years) | 64 ± 9 | |||
| Gender (female %) | 32% | |||
| Race (Caucasian %) | 92% | |||
| History of DM (%) | 39% | |||
| BMI (kg/m2) | 29.8 ± 4.5 | |||
| SBP (mmHg) | 137 ± 15 | |||
| DBP (mmHg) | 76 ± 9 | |||
| CKD-EPI eGFR (mL/min/1.73m2) | 36 ± 11 | |||
| ACR (mg/g) | 7.5 ± 17 | |||
| ACEi/ARB (%) | 64 | |||
Values are expressed as means ± standard deviation or % = percent of patients; DM = diabetes mellitus; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; CKD-EPI eGFR = CKD-EPI estimated glomerular filtration rate; ACR = urinary albumin/creatinine ratio; ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor II blocker.
*CKD only.